Diagnostic tools: Various tests to diagnose and manage hepatitis C including various biochemical marker, imaging, liver biopsy for grading/staging liver disease and HCV RNA (viral load) tests.


·        Biochemical/Imaging

o       181. Ratio Interquartile Range / Median Value of Liver Stiffness Measurement is a Key Factor of Accuracy of Transient Elastography (FIBROSCAN®) for the Diagnosis of Liver Fibrosis

o       182. Performance of non-invasive methods in the assessment of disease severity in routine clinical practice in patients with chronic hepatitis C

o       184. Comparison of MR elastography, ultrasound elastography and APRI for the non-invasive assessment of liver fibrosis

o       185. Fibrotest versus liver biopsy: An independent multicenter evaluation of performance

o       186. Prospective comparison of two algorithms combining non invasive tests for staging of liver fibrosis in chronic hepatitis C

o       1335. European Liver Fibrosis (ELF) panel of serum markers can predict clinical outcome in a cohort of patients from England with mixed aetiology chronic liver disease

o       1338. Diagnostic Accuracy of the APRI for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review

o       1339. Comparison of reproducibility of histology, blood tests and Fibroscan for liver fibrosis (updated November 6, 2007)

o       1344. Interobserver Reproducibility of Liver Stiffness Measurement by Transient Elastography (FIBROSCAN®)

o       1346. The result of liver stiffness measurement is influenced by the serum bilirubin level

o       1348. Accurate Identification of Liver Fibrosis Using the Point-Of-Care Continuous 13C Methacetin Breath Test: A Decision Making Tool in the Treatment of Patients with Chronic HCV Infection (updated November 6, 2007)

o       1351. Serum levels of sH2a, a secreted form of the asialoglycoprotein receptor, as a non-invasive sensitive marker for liver function

o       1355. Can platelet count or APRI be the poor man’s Transient Elastography in HCV patients?

o       1363. Comparison of two real-time PCR based assays (RealTime HCV, Cobas TaqMan) with a signal amplification assay (bDNA) for HCV RNA detection

o       1365. Fibrosis stages determination, reproducibility and robustness of blood tests for liver fibrosis in chronic hepatitis C

o       1367. The APRI Can Negatively Predict Cirrhosis in Patients With Chronic Hepatitis C (HCV) (updated November 6, 2007)

o       1368. Prospective comparison of two commercial non-invasive fibrosis serum marker panels (FibroSure and FibroSpect II) during interferon-based combination therapy in chronic HCV genotype 1

o       1369. A practical index (FibroIndex) for the prediction of significant fibrosis in patients with chronic hepatitis C


·        Biopsy

o       1325. Correlation between liver biopsy and FibroSURETM during screening for a Phase II study to assess the antifibrotic activity of Farglitizar in chronic hepatitis C infection

o       1342. Large scale validation of the SAFE (Sequential Algorithms for Fibrosis Evaluation) biopsy in chronic hepatitis C (updated November 9, 2007)


·        General

o       1349. Iron overload does not effect the quantification of fibrosis by Liver Stiffness Measurement

o       1373. Higher Level of Alanine Aminotransferase Mass in Liver Disease Patients Than Normal Population Measured by Sandwich ELISA

o       1374. In vivo detection of caspase activity in patients with chronic hepatitis C as a novel biomarker of disease severity


·        Viral load

o       1299. What is the impact of higher sensitivity assay on response-guided therapy in hepatitis C virus (HCV)? Comparative analysis between TaqMan™ and Amplicor™ tests from two large randomized international trials of PEGASYS® plus COPEGUS®